Pair page
CJC-1295 with IGF-1 DES
Mechanism-tag overlap and published literature for CJC-1295 and IGF-1 DES, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
ghrhgrowth-hormone-releasing-hormone-analog
igf-1-receptor-agonistmodified-proteinn-terminally-truncated-analog
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying CJC-1295 and IGF-1 DES have published these mechanism-level observations. Not a co-administration recommendation.
GH secretagogues drive endogenous pulsatile GH and downstream IGF-1 production; IGF-1 DES adds direct receptor agonism at the target site. Mechanistically parallel; compounds systemic IGF-1 exposure.
Quick facts
CJC-1295
IGF-1 DES
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2006 | CJC-1295 | aidsmap. Lipodystrophy study halted after patient death. July 2006. (Reports the ConjuChem Phase 2 CJC-1295 trial halt.) | human trial, Phase 2 |
| 2010 | CJC-1295 | Alexopoulou O, Abs R, Maiter D. Treatment of adult growth hormone deficiency: who, why and how? A review. Acta Clin Belg. 2010;65(1):13-22. PMID: 20373593. PMID 20373593 | human study |
| 2009 | CJC-1295 | Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. PMID: 19540144. PMID 19540144 | human study |
| 2006 | CJC-1295 | Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805… PMID 16352683 | human study |
| 2006 | CJC-1295 | Abla AA, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E… PMID 16835399 | preclinical, in vivo |
| 2005 | CJC-1295 | Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology.… PMID 15817669 | preclinical, in vivo |
| 2005 | CJC-1295 | Alba M, Fintini D, Bowers CY, Parlow AF, Salvatori R. Effects of long-term treatment with growth hormone-releasing peptide-2 in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2005;289(5):E762-E767. | preclinical, in vivo |
| 2020 | CJC-1295 | Ishida J, Saitoh M, Ebner N, Springer J, Anker SD, von Haehling S. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Commun. 2020;3(1):25-37. | mechanism / discovery |
| 1995 | CJC-1295 | Izdebski J, Pinski J, Horvath JE, Halmos G, Groot K, Schally AV. Synthesis and biological evaluation of superactive agonists of growth hormone-releasing hormone. Proc Natl Acad Sci USA. 1995;92(10):4872-4876. PMID: 7761412. (Parent work on tetrasubstituted GHRH analogs.) PMID 7761412 | mechanism / discovery |
| 2023 | CJC-1295 | Alwatban MZ, Al-Lohedan HA. A review of CJC-1295 as a GHRH analog: Pharmacology and clinical relevance. Drug Des Devel Ther. 2023 (review series). | review |
| 2026 | CJC-1295 | World Anti-Doping Agency. The 2026 Prohibited List. Section S2 — Peptide Hormones, Growth Factors, Related Substances and Mimetics. wada-ama.org. | regulatory / registry |
| 2025 | CJC-1295 | U.S. Food and Drug Administration. Bulk Drug Substances That Raise Significant Safety Risks (Category 2) Under Section 503A / 503B. FDA.gov. Updated 2025. | regulatory / registry |
| 2002 | IGF-1 DES | Philipps AF, Kling PJ, Grille JG, Dvoráková S. Intestinal transport of insulin-like growth factor-I (IGF-I) in the suckling rat. J Pediatr Gastroenterol Nutr. 2002;35(4):539-544. PMID: 12394383. (Colostrum IGF-1 DES context.) PMID 12394383 | preclinical, in vivo |
| 1993 | IGF-1 DES | Tomas FM, Knowles SE, Chandler CS, Francis GL, Owens PC, Ballard FJ. Anabolic effects of insulin-like growth factor-I (IGF-I) and an IGF-I variant in normal female rats. J Endocrinol. 1993;137(3):413-421. PMID: 8371077. (In vivo anabolic effects of IGF-1 DES vs native IGF-1.) PMID 8371077 | preclinical, in vivo |
| 1991 | IGF-1 DES | Ballard FJ, Knowles SE, Walton PE, Edson K, Owens PC, Mohler MA, Ferraiolo BL. Plasma clearance and tissue distribution of labelled insulin-like growth factor-I (IGF-I), des(1-3)IGF-I and IGF-II in rats. J Endocrinol. 1991;131(1):87-93. PMID: 1720984. PMID 1720984 | preclinical, in vivo |
| 1991 | IGF-1 DES | Williams ED, et al. Comparison of des(1-3)IGF-1 and IGF-1 in promoting wound healing. Growth Factors. 1991 context. (Wound-healing preclinical reference.) | preclinical, in vivo |
| 1989 | IGF-1 DES | Sara VR, Carlsson-Skwirut C, Bergman T, Jörnvall H, Roberts PJ, Crawford M, Håkansson LN, Civalero I, Nordberg A. Identification of Gly-Pro-Glu (GPE), the aminoterminal tripeptide of insulin-like growth factor 1 which is truncated in brain, as a novel neuroactive peptide. Bioche… PMID 2597159 | mechanism / discovery |
| 1988 | IGF-1 DES | Francis GL, Upton FM, Ballard FJ, McNeil KA, Wallace JC. Insulin-like growth factors 1 and 2 in bovine colostrum. Sequences and biological activities compared with those of a potent truncated form. Biochem J. 1988;251(1):95-103. PMID: 3401742. (Seminal characterization of IGFBP-… PMID 3401742 | mechanism / discovery |
| 1986 | IGF-1 DES | Sara VR, Carlsson-Skwirut C, Andersson C, Hall E, Sjögren B, Holmgren A, Jörnvall H. Characterization of somatomedins from human fetal brain: identification of a variant form of insulin-like growth factor I. Proc Natl Acad Sci USA. 1986;83(13):4904-4907. PMID: 3459178. (Original… PMID 3459178 | mechanism / discovery |
| 2026 | IGF-1 DES | WADA. 2026 World Anti-Doping Code Prohibited List. Section S2 — Peptide hormones, growth factors, related substances and mimetics. World Anti-Doping Agency. (IGF-1 and analogs class prohibition.) | regulatory / registry |
| 2005 | IGF-1 DES | U.S. Food and Drug Administration. Increlex (mecasermin) Prescribing Information. Ipsen Biopharmaceuticals. First approved 2005. (Context: FDA-approved recombinant native IGF-1 — different molecule from IGF-1 DES.) | regulatory / registry |
| 2012 | IGF-1 DES | Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer. 2012;12(3):159-169. PMID: 22473468. (IGF-1 pathway and cancer epidemiology — central class-level safety framing.) PMID 22473468 | research article |
| 2003 | IGF-1 DES | LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett. 2003;195(2):127-137. PMID: 12767520. PMID 12767520 | research article |
| 2001 | IGF-1 DES | Musarò A, McCullagh K, Paul A, Houghton L, Dobrowolny G, Molinaro M, Barton ER, Sweeney HL, Rosenthal N. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet. 2001;27(2):195-200. PMID: 11175789. (Foundational muscle-s… PMID 11175789 | research article |
Related pair pages
More research context
Frequently asked
Have CJC-1295 and IGF-1 DES been studied together?
Researchers have published mechanistic-level co-administration discussion of CJC-1295 and IGF-1 DES. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do CJC-1295 and IGF-1 DES share?
CJC-1295 and IGF-1 DES do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of CJC-1295 and IGF-1 DES?
CJC-1295: Not approved. IGF-1 DES: Not approved; research only. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on CJC-1295 and IGF-1 DES?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the CJC-1295 profile and the IGF-1 DES profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026